Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov;159(2-3):491-8.
doi: 10.1016/j.schres.2014.08.025. Epub 2014 Sep 26.

Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficit

Affiliations

Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficit

Lauren E Ethridge et al. Schizophr Res. 2014 Nov.

Abstract

Difficulty inhibiting context-inappropriate behavior is a common deficit in psychotic disorders. The diagnostic specificity of this impairment, its familiality, and its degree of independence from the generalized cognitive deficit associated with psychotic disorders remain to be clarified. Schizophrenia, schizoaffective and bipolar patients with history of psychosis (n=523), their available first-degree biological relatives (n=656), and healthy participants (n=223) from the multi-site B-SNIP study completed a manual Stop Signal task. A nonlinear mixed model was used to fit logistic curves to success rates on Stop trials as a function of parametrically varied Stop Signal Delay. While schizophrenia patients had greater generalized cognitive deficit than bipolar patients, their deficits were similar on the Stop Signal task. Further, only bipolar patients showed impaired inhibitory control relative to healthy individuals after controlling for generalized cognitive deficit. Deficits accounted for by the generalized deficit were seen in relatives of schizophrenia and schizoaffective patients, but not in relatives of bipolar patients. In clinically stable patients with psychotic bipolar disorder, impaired inhibitory behavioral control was a specific cognitive impairment, distinct from the generalized neuropsychological impairment associated with psychotic disorders. Thus, in bipolar disorder with psychosis, a deficit in inhibitory control may contribute to risk for impulsive behavior. Because the deficit was not familial in bipolar families and showed a lack of independence from the generalized cognitive deficit in schizophrenia spectrum disorders, it appears to be a trait related to illness processes rather than one tracking familial risk factors.

Keywords: Family study; Psychotic bipolar disorder; Response inhibition; Schizophrenia; Stop signal.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest. Author RSEK currently or in the past has received investigator-initiated research funding support from the Allon, AstraZeneca, Department of Veteran's Affair, Feinstein Institute for Medical Research, GlaxoSmithKline, National Institute of Mental Health, Novartis, Psychogenics, Research Foundation for Mental Hygiene, Inc., and the Singapore National Medical Research Council. He currently or in the past has received honoraria, served as a consultant, or advisory board member for Abbott, Abbvie, Akebia, Amgen, Astellas, Asubio, BiolineRx, Biomarin, Boehringer-Ingelheim, BrainCells, Bristol-Myers Squibb, CHDI, Eli Lilly, EnVivo, Helicon, Lundbeck, Memory Pharmaceuticals, Merck, Mitsubishi, NeuroSearch, Novartis, Orion, Otsuka, Pfizer, Roche, Shire, Solvay, Sunovion, Takeda, Targacept, and Wyeth. RSEK also receives royalties from the BACS testing battery and the MATRICS Battery (BACS Symbol Coding). He is also a shareholder in NeuroCog Trials, Inc. Author GDP- consulted for Bristol-Myers Squibb. Author CAT discloses the following financial interests and associations: Intracellular Therapies (ITI, Inc.) - Advisory Board, drug development; PureTech Ventures- Ad Hoc Consultant; Eli Lilly Pharmaceuticles – Ad Hoc Consultant; Sunovion – Ad Hoc Consultant; Astellas – Ad Hoc Consultant; Merck – Ad Hoc Consultant; International Congress on Schizophrenia Research - Organizer; Unpaid volunteer; NAMI – Council Member; Unpaid Volunteer; American Psychiatric Association - Deputy Editor; Finnegan Henderson Farabow Garrett & Dunner, LLP – Expert Witness. Author MSK has received a grant from Sunovion Pharmaceuticals Inc. Author JAS has served as a consultant for Takeda, Inc., Eli Lilly Pharmaceuticals, BMS, and Roche and has received grant funding from Janssen, Inc. The remaining authors (LEE, MS, PAN, JLR, SKH, ESG) report no competing interests.

Figures

Figure 1
Figure 1
Stop Signal task parameters. In Go trials, participants pressed the corresponding left or right button when a green circle appeared to the right or left of center. During Stop trials, they were to refrain from pushing the buttons. When participants did not respond within 650 ms on Go trials, a red ‘X’ and the word ‘faster’ were presented for 2500ms indicating that the participant failed a trial. On Stop trials in which the participants pressed a button, a red ‘X’ appeared over the stop sign to provide performance feedback indicating the failure to inhibit a response.
Figure 2
Figure 2
Nonlinear mixed model curves for patient groups and healthy participants, without the inclusion of the BACS covariate. Values for Stop Signal Delay on the X axis represent median Stop Signal delays for each of 14 time bins.
Figure 3
Figure 3
Nonlinear mixed model curves for relative groups and healthy participants, without the inclusion of the BACS covariate. Values for Stop Signal Delay on the X axis represent median Stop Signal delays for each of 14 time bins.
Figure 4
Figure 4
Comparison of standardized relative deficit (Hedges' g) in parameter b1 (the Stop Signal Delay yielding a 50% error rate) in the SST (left plot) versus general cognitive deficit as measured by the BACS (right plot). All patient groups show significant deficit relative to healthy participants for both SST parameter b1 and BACS, but while SST b1 does not differ across patient groups, BACS deficits decrease across the spectrum of nonaffective and affective psychotic disorders from SZ to BPP.
Figure 5
Figure 5
Strategic slowing. Slowing of Go trial latencies by group, showing that all patient groups had significantly less strategic slowing during the SST relative to the baseline Go task than did healthy participants. HP: Healthy; SZ: Schizophrenia; SZA-D: Schizoaffective depressed type; SZA-BP: Schizoaffective bipolar type; BPP: Bipolar psychosis, * p<.05. all differences from BPP, ** p<.01, all differences from healthy participants

References

    1. Allen AJ, Griss ME, Folley BS, Hawkins KA, Pearlson GD. Endophenotypes in schizophrenia: a selective review. Schizophr Res. 2009;109(1-3):24–37. - PMC - PubMed
    1. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet. 1998;62(5):1198–1211. - PMC - PubMed
    1. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67(3):255–262. - PMC - PubMed
    1. Becker TM, Kerns JG, Macdonald AW, 3rd, Carter CS. Prefrontal dysfunction in first-degree relatives of schizophrenia patients during a Stroop task. Neuropsychopharmacology. 2008;33(11):2619–2625. - PubMed
    1. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: a Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. 1995;57(B):289–300.

Publication types

MeSH terms